PMCB (PharmaCyte Biotech) Buyback Yield %: 2.08 (As of Jul. 01, 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.77
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Buyback Yield %?

PharmaCyte Biotech PMCB +5.34% 32 Buyback Yield % is 2.08 as of Jul. 01, 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 745 Biotechnology companies, PharmaCyte Biotech ranks better than 96.11% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

PharmaCyte Biotech's current buyback yield was 2.08%.

PharmaCyte Biotech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Buyback Yield % Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.12 -180.95 27.65 165.48 30.16

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.00 30.16 25.98 6.28 1.96

PMCB vs ERNA, SYBX, ASBP: Buyback Yield % Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Buyback Yield % falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

PharmaCyte Biotech's Buyback Yield for the fiscal year that ended in Apr. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-2.542 + 0) / 8.42704
=30.16%

PharmaCyte Biotech's annualized Buyback Yield for the quarter that ended in Jan. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.172 + 0) / 8.792784
=1.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 2.08 mean?
PharmaCyte Biotech (PMCB) has a Buyback Yield % of 2.08 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #29 out of 745 companies in the Biotechnology industry, placing it in the top 3.9%.
Is PharmaCyte Biotech's Buyback Yield % too high?
PharmaCyte Biotech's current Buyback Yield % is 2.08. Based on the distribution chart, PharmaCyte Biotech ranks #29 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Buyback Yield % compare to ERNA and SYBX?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #29 out of 745 companies for Buyback Yield %. This places PharmaCyte Biotech in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Buyback Yield % is 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Buyback Yield % of 2.08. The current Buyback Yield % is 2.08. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Buyback Yield % is 2.08 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price